Zirconium dioxide nanoparticle loaded doxorubicin administered through different ways for treatment of hepatic VX2 transplanted tumor in rabbit models / 中国介入影像与治疗学

ABSTRACT

Objective: To compare tumor growth and drug targeting of zirconium dioxide nanoparticles loaded doxorubicin (DOX@ZrO2) and free doxorubicin (DOX-Free) administered through different routes of hepatic VX2 transplanted tumor in rabbit models. Methods: A total of 25 rabbit models of hepatic VX2 transplanted tumor were established and randomly divided into 5 groups, including group A (DOX@ZrO2 via hepatic artery), group B (DOX@ZrO2 via peripheral vein), group C (DOX-free via hepatic artery), group D (DOX-free via peripheral vein) and group E (untreated group). Tumor volumes were measured with CT scanning 1 day, 3 days and 6 days after drug administration, and the ratio of tumor volume were compared between 3 days and 1 day, 6 days and 3 days, as well as 6 days and 1 day. One-way ANOVO analysis was used for multi-group comparison and LSD or SNK method was used for pairwise comparison. Histological observations of isolated heart specimen were performed to evaluate the cardiotoxicity of the drug in each group. Results: There was no statistic difference of tumor volume ratio between 3 days and 1 day, nor between 6 days and 3 days (F=2.056, 1.906, P=0.125, 0.149), while statistic difference of tumor volume ratio was found between 6 days and 1 day after drug administration (F=4.230, P=0.012). The tumor volume ratio in group A was significantly lower than that in the other groups (P0.05) except between group B and E. Histological observation showed that the myocardium of group A and group B was just a little or no damage, while of group C and group D were severe damaged. Conclusion: Combining traditional super selective hepatic arterial chemotherapy targeting surgical treatment method with nano drug carrier, tumor growth of hepatic VX2 transplanted tumor in rabbit model can be delayed, and the drug targeting can be improved. Moreover, the cardiotoxicity caused by doxorubicin can be effectively reduced.